BC
CLDX icon

Bayforest Capital’s Celldex Therapeutics CLDX Stock Holding History

Bayforest Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-865
Closed -$21.9K – 750
2024
Q4 		$21.9K Buy
+865
New +$23.5K 0.03% 564

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bayforest Capital's CLDX Position: Q1 2025 in Review

Bayforest Capital sold out of Celldex Therapeutics (CLDX) in Q1 2025, closing a stake of 865 shares — an estimated $21.9K sold.

Bayforest Capital first reported a position in CLDX in Q4 2024 and held it in 1 quarter. The position peaked at $21.9K in Q4 2024. 171 funds tracked by Wall St. Rank hold CLDX as of Q1 2025.

  • Bayforest Capital reported no remaining Celldex Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bayforest Capital sold 865 Celldex Therapeutics shares in Q1 2025, an estimated $21.9K.
  • Bayforest Capital first reported a position in Celldex Therapeutics in Q4 2024 and held it in 1 quarter.
  • Bayforest Capital's Celldex Therapeutics position peaked at $21.9K in Q4 2024.
  • 171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2025.

Based on Bayforest Capital's 13F filing for Q1 2025, filed 8 May 2025.